Communiqués Nektar Therapeutics

Actions

NKTR

US6402683063

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 17:19:02 04/09/2026			Varia. 5j.	Varia. 1 janv.
73,76 ^USD	-3,41%		+1,77%	+74,55%

25/08	Nektar Therapeutics publie les résultats positifs de la période d'induction de 16 semaines de l'étude de phase 2b REZOLVE-AD sur le rezpegaldesleukin dans la dermatite atopique modérée à sévère	CI
14/08	Transcript : Nektar Therapeutics, Q2 2026 Earnings Call, Aug 13, 2026

Communiqués

31/08	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	AQ
28/08	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	PR
25/08	Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis	PR
13/08	Nektar: Q2 Earnings Snapshot	AQ
13/08	Nektar Therapeutics Announces Second Quarter 2026 Financial Results	PR
29/07	Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets	PR
24/07	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	PR
21/07	Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis	PR
26/06	Nektar Therapeutics : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	PU
03/06	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	PR
28/05	Nektar Therapeutics : to Participate in the 2026 Jefferies Global Healthcare Conference in New York	PU
07/05	Nektar: Q1 Earnings Snapshot	AQ
07/05	Nektar Therapeutics Reports First Quarter 2026 Financial Results	PR
04/05	NKTR INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026	NE
02/05	NKTR CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026	NE
01/05	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	PR
29/04	Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets	PR
28/04	NKTR DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026	NE
25/04	NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026	NE
23/04	Nektar Therapeutics Class Action Reminder – Robbins LLP Encourages NKTR Investors to Contact the Firm for Information About Their Rights	BU
23/04	Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares	PR
23/04	NKTR CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026	NE
22/04	Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering	PR
21/04	NEKTAR THERAPEUTICS (NKTR) DEADLINE ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline	NE
20/04	Nektar Therapeutics Announces Proposed Public Offering	PR